Device-less patent foramen ovale closure by radiofrequency thermal energy

被引:0
作者
Walpoth, Nazan B. [1 ]
Habermacher, Kathrin [1 ]
Moarof, Igal [1 ]
Watson, Sandy [1 ]
Wahl, Andreas [1 ]
Windecker, Stephan [1 ]
Schoenenberger, Christa [1 ]
Meier, Bernhard [1 ]
机构
[1] Univ Hosp Bern, Cardiovasc Dept, CH-3010 Bern, Switzerland
关键词
patent foramen ovale; cardiac catheterisation; device-less closure; radiofrequency energy;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The goal of this study was to assess the feasibility, safety and success of a system which uses radiofrequency energy (RFE) rather than a device for percutaneous closure of patent foramen ovale (PFO). Methods: Sixteen patients (10 men, 6 women, mean age 50 years) were included in the study. All of them had a proven PFO with documented right-to-left shunt (RLS) after Valsalva manoeuvre (VM) during transoesophageal echocardiography (TEE). The patients had an average PFO diameter of 6 +/- 2 mm at TEE and an average of 23 +/- 4 microembolic signals (MES) in power M-mode transcranial Doppler sonography (pm-TCD), measured over the middle cerebral artery. An atrial septal aneurysm (ASA) was present in 7 patients (44%). Balloon measurement, performed in all patients, revealed a stretched PFO diameter of 8 +/- 3 mm. In 2 patients (stretched diameter 11 and 14 mm respectively, both with ASA >10 mm), radiofrequency was not applied (PFO too large) and the PFO was closed with an Amplatzer PFO occluder instead. A 6-month follow-up TEE was performed in all patients. Results: There were no serious adverse events during the procedure or at follow-up (12 months average). TEE 6 months after the first RFE procedure showed complete closure of the PFO in 50% of the patients (7/14). Closure appeared to be influenced by PFO diameter, complete closure being achieved in 89% (7/8) with a balloon-stretched diameter: 7 mm but in none of the patients >7 mm. Only one of the complete closure patients had an ASA. Of the remainder, 4 (29%) had an ASA. Although the PFO was not completely closed in this group, some reduction in the diameter of the PFO and in MES was documented by TEE and pm-TCD with VM. Five of the 7 residual shunt patients received an Amplatzer PFO occluder. Except for one patient with a minimal residual shunt, all showed complete closure of PFO at 6-month follow-up TEE and pm-TCD with VM. The other two refused a closure device. Conclusions: The results confirm that radiofrequency closure of the PFO is safe albeit less efficacious and more complex than device closure. The technique in its current state should not be attempted in patients with a balloon-stretched PFO diameter >7 mm and an ASA.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [41] Transcatheter closure of patent foramen ovale with the Spider™ patent foramen ovale occluder: a prospective, single-center trial
    Zhang Cao-jin
    Huang Yi-gao
    Huang Xin-sheng
    Huang Tao
    Huang Wen-hui
    Shen Jun-jun
    Xun Zheng-rong
    CHINESE MEDICAL JOURNAL, 2010, 123 (07) : 834 - 837
  • [42] Patent foramen ovale closure and migraine: science and sensibility
    Gupta, Vinod Kumar
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (09) : 1409 - 1422
  • [43] Percutaneous Patent Foramen Ovale Closure After Stroke
    Lee, Oh-Hyun
    Kim, Jung-Sun
    KOREAN CIRCULATION JOURNAL, 2022, 52 (11) : 801 - 807
  • [44] Residual Shunt after Patent Foramen Ovale Closure: Preliminary Results from Italian Patent Foramen Ovale Survey
    Caputi, Luigi
    Butera, Gianfranco
    Anzola, Gian Paolo
    Carminati, Mario
    Carriero, Maria Rita
    Chessa, Massimo
    Onorato, Eustaquio
    Rigatelli, Gianluca
    Sangiorgi, Giuseppe
    Santoro, Gennaro
    Spadoni, Isabella
    Ussia, Gian Paolo
    Vigna, Carlo
    Zanchetta, Mario
    Parati, Eugenio
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2013, 22 (07) : E219 - E226
  • [45] Safety and Efficacy of Patent Foramen Ovale Device Closure: Evaluation of Outcomes in a Tertiary Referral Center
    Favaedi, Maryam
    Danesh-Moghadam, Maryam
    Khajali, Zahra
    Firouzi, Ata
    Parsaee, Mozhgan
    Saedi, Sedigheh
    RESEARCH IN CARDIOVASCULAR MEDICINE, 2023, 12 (02) : 52 - 55
  • [46] Infective Endocarditis of Patent Foramen Ovale Closure Device Presenting as an Amoeboid-Like Mass
    Yamaoka, Hidenaru
    Takaya, Yoichi
    Watanabe, Nobuhisa
    Akagi, Teiji
    Nakagawa, Koji
    Toh, Norihisa
    Kotani, Yasuhiro
    Kasahara, Shingo
    Ito, Hiroshi
    JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (22) : 2237 - 2338
  • [47] Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure
    Korabathina, Ravikiran
    Thaler, David E.
    Kimmelstiel, Carey
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 80 (03) : 498 - 502
  • [48] Embolization of Patent Foramen Ovale Closure Device-Rare Complication and Unique Management Approach
    Kovacevic, Mila
    Atanaskovic, Marko
    Obradovic, Katarina
    Todic, Mirko
    Crnomarkovic, Branislav
    Bjelobrk, Marija
    Bjelic, Snezana
    Cankovic, Milenko
    Milovancev, Aleksandra
    Srdanovic, Ilija
    MEDICINA-LITHUANIA, 2024, 60 (05):
  • [49] Transseptal puncture for catheter ablation of atrial fibrillation after device closure of patent foramen ovale
    Zaker-Shahrak, Ruzbeh
    Fuhrer, Juerg
    Meier, Bernhard
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2008, 71 (04) : 551 - 552
  • [50] Approval, Evidence, and "Off-Label" Device Utilization: The Patent Foramen Ovale Closure Story
    Goldsweig, Andrew M.
    Deng, Yihong
    Yao, Xiaoxi
    Desai, Nihar R.
    Cohen, David J.
    Aronow, Herbert D.
    Messe, Steven R.
    Ross, Joseph S.
    Lansky, Alexandra J.
    Savitz, Samuel T.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (01): : E010200